The presence of p62 protein increases the likelihood of liver cancer recurrence and significantly reduces the survival rate of patients. Such a conclusion was made by Professor Michael Karin and his colleagues at the University of California, studying the recurrence of the disease in mice.
They noticed that if after removal of the tumor in the liver tissues was observed a high level of p62, a relapse occurred much more frequently. Moreover, scientists have found that in the absence of protein in the tumor tissue does not develop.
In the case of the liver cancer patients have low survival rates, because the symptoms appear at the late stage of the disease. Therefore, the researchers hypothesized that p62 can be used as a marker for new treatments and relapse prevention.
P62 function is that it "collects" unnecessary metabolic products and send them for recycling. In addition, it controls the growth and viability of the cells. In connection with this protein contributes to the development of cancer cells, preventing their death.
Previously, scientists have found high levels of p62 protein in a variety of cancer cells and their precancerous condition. Further studies were carried out on the tissues affected by hepatocellular carcinoma - the most common form of liver cancer.
In the first stage considered the possibility of recurrence in patients prepared to remove the tumor. It was found that the greater the protein p62 in the tissues, the less likely people were to survive.
Next step using mice revealed that activates p62 and other proteins that are involved in tumor development. At the same time in mice whose figure protein level was zero, liver cancer does not develop.
Michael Karin says that the discovery of p62 will allow to predict the likelihood of recurrence of the disease after tumor removal. A detection of substances that disrupt protein p62 work to provide new drugs to prevent the transformation of chronic liver disease in cancer.
Based on materials medicalnewstoday.com